Previsão

O preço-alvo médio dos analistas é € 93,10 (+60,19%). A mediana é € 92,22 (+58,67%).

Comprar	11
Manter	0
Vender	0

Notícias Ir para o feed de notícias

Disc Medicine presents pipeline ahead of pivotal clinical and regulatory tests

At a Morgan Stanley conference, Disc Medicine pointed to several upcoming milestones: Phase III data for bitopertin (APOLLO) in EPP are expected in Q4 2024. The company reports cash and equivalents of $780 million and sees a financing runway through 2029. DISC-0974 showed consistent response rates in myelofibrosis-associated anemia; an end-of-phase-II meeting with the FDA is still planned for 2024. DISC-3405 produced positive Phase II signals in polycythemia vera and is targeting Phase III starts in 2025. » Mais em de.investing.com
Disc Medicine reports positive phase‑2 results for DISC‑3405

Disc Medicine presented initial data from the Phase‑2 study RESTORE‑PV: DISC‑3405 increased hepcidin, lowered serum iron and reduced the need for phlebotomies in patients with polycythaemia vera. In cohort A (300 mg every two weeks) the average number of phlebotomies over 26 weeks fell from 4.0 to 0.6; 61.5% remained apheresis‑free for 26 weeks, and hematocrit stayed below 45% through week 26. DISC‑3405 was overall well tolerated, with mostly mild, self‑limiting injection reactions. The company plans a study update and initial data from a Phase‑1b study in sickle cell disease by year‑end. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Disc Medicine registou receitas de € 0 e um ganho líquido de -€ 52,16 mi

(EUR)	junho de 2026	YoY
Receitas	0	-
Ganho bruto	0	-
Ganho líquido	-52,16 mi	11,29%
EBITDA	-51,23 mi	11,40%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 2,23 bi
Número de ações	38,39 mi
Máximo/mínimo de 52 semanas	€ 87,39 - € 35,13
Dividendos	Não
Beta	2,05
PER (PE Ratio)	-10,01
PEG (PEG Ratio)	0,27
P/VC (PB Ratio)	3,97
P/V (PS Ratio)	0,00

Perfil da empresa

Disc Medicine, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich mit der Entdeckung, Entwicklung und Vermarktung neuartiger Behandlungsmethoden für Patienten mit schweren hämatologischen Erkrankungen befasst. Es baut ein Portfolio von therapeutischen Kandidaten auf, die ein Spektrum von hämatologischen Erkrankungen ansprechen, indem sie auf grundlegende biologische Wege der Biologie der roten Blutkörperchen abzielen, vor allem auf die Häm-Biosynthese und die Eisen-Homöostase. Das Unternehmen hat seinen Sitz in Watertown, Massachusetts.